Latest filing published 21 Jan 2026 for Cabaletta Bio, Inc., €86k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Steven Nichtberger (chief executive) discloses dealings in 2 companies, chiefly Cabaletta Bio, Inc. and Tengion Inc. The record holds 7 filings, for trades running from 14 April 2010 to 21 January 2026.
On the market, this insider has only ever bought: 3 purchases, €239k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant and 1 option exercise. 2026 to date brings 1 purchase and no sales.
The median purchase comes to €86k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 21 January 2026 with an open-market purchase (€86k) in Cabaletta Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations